OliClinomel N4-550E/OliClinomel N7-1000E

Per 1,000 mL infusion bag OliClinomel N4-550E Lipid emulsion (80% olive oil + 20% soybean oil) 20 g, glucose 80 g, amino acids 22 g, nitrogen 3.6 g, electrolytes. Energy: 610 kCal. OliClinomel N7-1000E Lipid emulsion (80% olive oil + 20% soybean oil) 40 g, glucose 160 g, amino acids 40 g, nitrogen 6.6 g, electrolytes. Energy: 1,200 kCal

Parenteral nutrition for adults & childn >2 yr when oral or enteral nutrition is impossible, insufficient or contraindicated.

Average nitrogen requirement: 0.16-0.35 g/kg daily. Average daily fluid requirement: 1-1.5 mL per expended kCal. OliClinomel N4-550E Adult Max daily dose: 40 mL/kg (equiv to amino acids 0.88 g, glucose 3.2 g, lipids 0.8 g, Na 0.84 mmol, K 0.64 mmol per kg). Childn >2 yr Recommended max daily dose: 50 mL/kg fluid, 1.1 g/kg amino acids, 4 g/kg glucose, 1 g/kg lipids. OliClinomel N7-1000E Adult Max daily dose: 33 mL/kg (equiv to amino acids 1.32 g, glucose 5.28 g, lipids 1.32 g, Na 1.06 mmol, K 0.79 mmol per kg). Childn 12-18 yr Recommended max daily dose: 36 mL/kg fluid, 1.4 g/kg amino acids, 5.8 g/kg glucose, 1.4 g/kg lipids. Childn 2-11 yr Recommended max daily dose: 45 mL/kg fluid, 1.8 g/kg amino acids, 7.2 g/kg glucose, 1.8 g/kg lipids.

Known hypersensitivity to active substances or egg or soya proteins. Congenital abnormality of amino acid metabolism; severe hyperlipidaemia or lipid metabolism disorders characterised by hypertriglyceridaemia; severe hyperglycaemia; pathologically elevated Na, K, Mg, Ca & P plasma conc. Premature neonates, infants & childn <2 yr.

Not to restart infusion in the same central vein. Not to connect bag in series to avoid possibility of gas embolism. Discontinue if any sign or symptom of allergic reaction eg, perspiration, fever, chills, headache, skin rashes, dyspnoea or bronchospasm develops; signs of pulmonary distress; extravasation occur. Cross-allergy between soya & peanut proteins; known allergy to corn or corn products. Severe water/electrolyte imbalance disorders, severe fluid overload conditions & serious metabolism disorders; infection of vascular access & septicaemia; fat overload syndrome; metabolic complications; advanced malnutrition resulting to refeeding syndrome. Patients w/ increased osmolarity, adrenal insufficiency, heart failure or pulmonary dysfunction; coagulation disorders and anaemia, metabolic acidosis, diabetes, hyperlipidaemia, amino acid metabolism disorders. Monitor water/electrolyte balance, serum osmolarity & triglycerides, acid/base balance, blood glucose, liver & renal function, coagulation tests & blood counts including platelet count throughout treatment. Regularly check serum triglyceride conc; not to exceed 3 mmol/L during infusion, & determine after at least 3 hr continuous infusion. Perform test & measure serum triglycerides after 5-6 hr period w/o lipids in lipid metabolism abnormality. Adjust infusion rate/administer insulin in the event of hyperglycaemia. Closely monitor fluid status. Monitor extravasation site at least every 4 hr during 1st 24 hr, then once daily. Concomitant use w/ ceftriaxone through the same infusion line. Hepatic insufficiency, including cholestasis or elevated liver enzymes. Renal insufficiency. Pregnancy & lactation. Childn <2 yr.

Infusion site swelling. Hyperglycaemia; diarrhea, vomiting, nausea; abnormal hepatic function; infusion site extravasation, pain & reaction, chest discomfort; increased hepatic enzyme, γ-glutamyltransferase, blood triglycerides & alkaline phosphatase.

Precipitation of ceftriaxone-Ca salt. Pseudoagglutination when administered simultaneously w/ blood through the same infusion tubing. Interference w/ results of lab tests eg, bilirubin, lactate dehydrogenase, O₂ saturation, blood Hb. Hyperkalaemia w/ K-sparing diuretics (eg, amiloride, spironolactone, triamterene), ACE inhibitors, angiotensin II receptor antagonists or tacrolimus, ciclosporin immunosuppressants.

Parenteral Nutritional Products

B05BA10 - combinations ; Belongs to the class of solutions for parenteral nutrition used in I.V. solutions.

D